In 2019 they described the effects of their phase 1b/2 clinical trial focusing on the effectiveness of ibrutinib in combination with PD-L1 inhibitor durvalumab in patients with pretreated stage-III/IV breast cancer, pancreatic adenocarcinoma and NSCLC. This evidence concerns the gene CD274 and breast cancer.